Abstract
Objective: To investigate the impact of oral propionate (PA) - a short chain fatty acid (SCFA) - on regualatory T cells (Treg) in healthy volunteers and multiple sclerosis (MS) patients in vivo. Background: In the in the small intestine, we have recently shown that depending on their chain length fatty acids (FA) either induce an in increase Th17 (long chain FA) or Treg differentiation (SCFA). Furthermore, we could show that while long chain FA have a detrimental effect on the course of experimental autoimmune encephalomyelitis (EAE), a model of MS, SCFA ameliorate EAE mainly by promoting the differentiation of Treg. Methods: In a proof of concept study (approved by the local ethics committee), we transferred our observations on PA to healthy individuals and MS patients by orally administrating PA (1g daily) - an approved food additive with no safety concerns - in capsules for 14-60 days. The study included washout intervals after 14-60 days. A detailed flow cytometry immunophenotypic assessment of T cell subsets before and at several time points after PA intake was performed, as well as additional functional correlates, such as in vitro suppression assays. Results: We report the first beneficial in vivo effects of PA in humans. PA intake was well tolerated by all volunteers and no side effects occurred. Treg frequencies in all treated individuals increased (up to 25-30[percnt]), which was accompanied by a significant decrease of Th17 cells. Increased Treg frequencies were maintained for 2-3 weeks after withdrawal of PA, and similar to baseline frequencies after 2 months of washout. Conclusions: Our results underline the influence of nutritive FA on systemic immune response und may be included in an add-on regimen of PA in addition to established first line MS drugs.
Disclosure: Dr. Haghikia has nothing to disclose. Dr. Duscha has nothing to disclose. Dr. Berg has nothing to disclose. Dr. Jörg has nothing to disclose. Dr. Wilck has nothing to disclose. Dr. Müller has nothing to disclose. Dr. Linker has nothing to disclose. Dr. Gold has received research support from Bayer HealthCare, Biogen Idec, Merck Serono, Novartis, and Teva Neuroscience.
Saturday, April 16 2016, 8:30 am-7:00 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.